Last update: July 10, 2014

Astemizole

High Risk for breastfeeding


Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.

Second generation anti-histaminic and pyperidine drug with a slightly sedative effect.
Withdrawn from the market in Spain because of an increased risk of ventricular arrhytmias

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Astemizole belongs to this group or family:

Tradenames

Main tradenames from several countries containing Astemizole in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 459 daltons
Tmax 2 hours
T1/2 312 hours

References

  1. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  2. Ghaeli P, Kaufman MB. Oral antihistamines/decongestants and breastfeeding. J Hum Lact. 1993 Abstract

Total visits

3,645

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM